Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI study of ABBV-903 and Midazolam
NCT05895266Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of limnetrelvir in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants with Adverse Events, Maximum Plasma Concentration and 4 more. Started Jun 2023; status: completed.
02
Drugs
limnetrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05895266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05895266.